CareDx prelim Q4 revenue ~$108M (+25% YoY); FY25 rev ~$380M (+14%)

CareDx, Inc.

2025-FY EPS reported -$0.40 revenue$379,805,000

Q4 testing services volume ~53,000 (+17% YoY); testing revenue ~$78M (+23%).
Patient & digital solutions revenue ~$17M (+47%); product revenue ~$13M (+17%).
Full-year 2025 revenue ~$380M; testing volume ~200,000 (+14%).
Share repurchases: $88M for 5.8M shares in 2025; $12M for 773K shares in Q4.
Cash, equivalents, and securities ~$200M as of Dec 31, 2025; no FY26 guidance given.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.